###begin article-title 0
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif and APOBEC3G: Multiple roads to one goal
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 131 139 131 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 569 583 569 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Retrovirology </italic>
###xml 38 73 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 75 80 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 435 440 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1071 1074 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The viral infectivity factor, Vif, of human immunodeficiency virus type 1, HIV-1, has long been shown to promote viral replication in vivo and to serve a critical function for productive infection of non-permissive cells, like peripheral blood mononuclear cells (PBMC). Vif functions to counteract an anti-retroviral cellular factor in non-permissive cells named APOBEC3G. The current mechanism proposed for protection of the virus by HIV-1 Vif is to induce APOBEC3G degradation through a ubiquitination-dependent proteasomal pathway. However, a new study published in Retrovirology by Strebel and colleagues suggests that Vif-induced APOBEC3G destruction may not be required for Vif's virus-protective effect. Strebel and co-workers show that Vif and APOBEC3G can stably co-exist, and yet viruses produced under such conditions are fully infectious. This new result highlights the notion that depletion of APOBEC3G is not the sole protective mechanism of Vif and that additional mechanisms exerted by this protein can be envisioned which counteract APOBEC3G and enhance HIV infectivity.
###end p 2
###begin title 3

###end title 3
###begin p 4
###xml 403 417 403 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Retrovirology </italic>
###xml 426 427 426 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 701 702 701 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 902 903 902 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 904 905 904 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1270 1271 1270 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1272 1273 1272 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 55 60 <span type="species:ncbi:9606">human</span>
###xml 372 377 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 597 602 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 779 784 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In contrast to most animal viruses, infection with the human and simian immunodeficiency viruses results in prolonged, continuous viral replication in the infected host. Remarkably, viral persistence is not thwarted by the presence of apparently vigorous, virus-specific immune responses. Several factors, including the evasion of an innate cellular anti-viral defense by HIV-1 as discussed in a recent Retrovirology article [1], are thought to contribute to persistent viral replication. Most notably during its course of engendering the development of acquired immunodeficiency syndrome (AIDS), HIV-1 mutates with high frequency and thus avoids immune response and intracellular defense mechanisms [2]. Interestingly, it has been observed for several years that the genomes of HIV-1, other retroviruses, and hepatitis B viruses show under certain conditions a very high rate of G-to-A hypermutation [2-5]. Earlier, this mutagenic phenomenon was attributed to the error-prone retroviral reverse transcriptase together with imbalances in the available deoxynucleotide pools in the cell. However, more recently a new player has been discovered, and new studies implicate the host cell cytidine deaminase APOBEC3G as responsible for G-to-A hypermutation in viral genomes [4,6].
###end p 4
###begin p 5
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 691 692 691 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 693 694 693 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 695 696 695 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 860 861 860 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
APOBEC3G is a virion-encapsidated cellular protein that deaminates dC to dU in minus-strand viral cDNA during reverse transcription [7-10]. The uracil-containing cDNA may then activate a cellular uracil-DNA-glycosidase causing the failure of reverse transcription. This failure is characteristic of Vif-defective virus and results in the impairment of proviral integration into the host genome [10,11]. Furthermore, even if the reverse transcription is completed at low efficiency and the resulting proviral double stranded cDNA is integrated into the cellular genome, the massive C-U conversion in the minus strand leads to pervasive G to A hypermutation of the proviral plus-strand cDNA [[5,7,8], and [10]]. Thus, APOBEC3G is a member of a group of innate cellular antiviral response factors that limit the damage inflicted by viruses to their hosts (Figure 1).
###end p 5
###begin p 6
###xml 69 74 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 137 142 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 237 242 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Schematic representation of Vif and APOBEC3G interactions during the HIV-1 replication cycle. Red arrows represent Vif action during the HIV-1 viral replication in non-permissive cells. Green arrows represent APOBEC3G/3F action in viral HIV-1 Vif defective virus. Broken arrows represent inhibition of APOBEC3G activity by Vif. Question marks (?) represent unresolved questions about Vif and APOBEC interactions. Box1: Schematic representation of minus-strand DNA and/or viral RNA deamination by APOBEC3G/3F [48]. Box2: Degradation model of APOBEC3G induced by Vif; Vif interacts with APOBEC3G as part of a Vif-Cul5-SCF complex resulting in the polyubiquitination and proteasomal degradation of APOBEC3G. Vif may have been derived from a cellular SOCS box protein that targets APOBEC 3G to the ECS ubiquitin ligase [49]. Two possible pathways of APOBEC3G regulation by Vif are represented.
###end p 6
###begin p 7
###xml 93 96 93 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vif</italic>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 562 565 562 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vif</italic>
###xml 783 785 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1133 1134 1133 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 87 92 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 205 210 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 324 329 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 556 561 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 733 738 <span type="species:ncbi:9606">human</span>
The effects of APOBEC3G and its G-to-A deaminase activity on the survival of wild type HIV-1 vif+ virus are not known; but, current observations are that APOBEC3G confers a major deleterious effect to the HIV-1 genome when the Vif protein is absent. Historically, Vif has been known to play a dramatically important role in HIV-1 infectivity [12,13]. Vif is a basic protein of 23 kDa which is packaged into virions and which is required in virus producing cells during the late stages of infection to enhance viral infectivity by 10-to-1000 folds [14-17]. HIV-1 vif-defective virus can replicate in some permissive cells such as Jurkat and SupT1 cells, but cannot replicate in other non-permissive cells such as macrophages, primary human T cells, and some restrictive T cell lines [18-20]. For a very long time, it was not known what determined the difference between a permissive versus a non-permissive cell. The answer to this long-standing puzzle came when Michael Malim's laboratory found that non-permissive cells contain the anti-viral cellular factor APOBEC3G, and that the anti-viral action of APOBEC3G is thwarted by Vif [4].
###end p 7
###begin p 8
###xml 218 219 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 898 900 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1301 1302 1301 1302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 204 209 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1260 1265 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Following on the heels of that initial observation, an enormous amount of effort emerged from several laboratories directed at elucidating how Vif mechanistically counteracts APOBEC3G in order to protect HIV-1 (Figure 1). Subsequent results showed remarkably that APOBEC3G binds Gag nucleocapsid NC protein, and in the absence of Vif, it is incorporated into the viral particle in close proximity to the reverse transcription complex [21]. Whether this interaction explains previous results on viral core stability or downstream effects during reverse transcription remains unclear [22]. Additionally, it was shown that Vif inhibited translation of APOBEC3G and/or its intracellular half-life [23-29]. In this regard, elegant biochemical studies showed that Vif interacted with APOBEC3G as part of a Vif-Cul5-SCF complex which led to the polyubiquitination and proteasomal degradation of APOBEC3G [30]. These latter results provided the mechanistic basis for the current accepted paradigm whereby increased degradation and/or reduced ambient level of APOBEC3G caused by Vif hinders the incorporation of APOBEC3G into virions. This consequently leads to an absence of APOBEC3G during reverse transcription in the virion-infected target cell, thereby permitting HIV-1 to replicate more robustly (Figure 1).
###end p 8
###begin p 9
###xml 18 27 18 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kao et al</italic>
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 533 534 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1425 1427 1425 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1428 1430 1428 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1511 1520 1511 1520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kao et al</italic>
###xml 1834 1846 1834 1846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Strack et al</italic>
###xml 1986 1988 1986 1988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 109 144 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Now the report by Kao et al. adds a new wrinkle to this model by demonstrating that production of infectious human immunodeficiency virus type 1 does not require physical depletion of APOBEC3G in the presence of Vif from virus-producing cells [1]. Kao's study is remarkable for the fact that it raises the possibility of an alternative mechanism of viral protection from APOBEC3G by Vif. Indeed, some previous studies have shown drastic effects of Vif on steady-state amounts of APOBEC3G while others have found only modest effects [4,25-29]. Using confocal microscopy, Strebel and co-workers directly compared different methods of immunofluorescence to evaluate the expression of APOBEC3G at the single-cell level in absence or presence of Vif. Strikingly, depending on the fixation method and antibodies used, the results obtained showed variations in the number of cells which express APOBEC3G and Vif concomitantly. Thus, it is conceivable that direct binding of Vif to APOBEC3G may have alterred the deaminase's conformation, covering epitopes recognized by some of the antibodies used to detect APOBEC3G. Notably, most published studies have used APOBEC3G tagged at its N-terminus or C-terminus. Nevertheless, it should be kept in mind that a possible conformational change in APOBEC3G triggered by Vif-binding may also expose hydrophobic domains that are recognized by the ubiquitination and/or degradation machinery [31,32]. Thus, ubiquitination of APOBEC3G may still occur under the conditions used by Kao et al, but as demonstrated by these authors no degradation of APOBEC3G ensued. In this respect, protein ubiquitination could be not only a signal for protein turnover, but also a signal for cellular localization. An illustrative example of this concept is the putative ubiquitination of p6 protein in which findings by Strack et al. suggested that the engagement of the ubiquitin conjugation machinery by L domains plays a crucial role in the release of enveloped virus [33].
###end p 9
###begin p 10
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 684 686 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1121 1123 1121 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1124 1126 1124 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1962 1972 1962 1972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kao et al </italic>
###xml 2086 2088 2086 2088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 2089 2091 2089 2091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 376 381 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1376 1396 <span type="species:ncbi:9534">African green monkey</span>
###xml 1501 1506 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1853 1858 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2006 2011 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
Many examples of allosteric alteration by protein-protein interaction are reported in the literature, and further work is necessary to evaluate possible conformational switches induced by Vif [34-36]. Bearing this in mind, it is noteworthy that a single amino acid substitution from D (aspartate)128 to K (lysine) in APOBEC3G can render this protein resistant to depletion by HIV-1 Vif [37-40]. It is possible that this amino acid represents a direct contact point for Vif, or that a change at this position influences the global conformation of the enzyme. Previous studies support the notion that this amino acid is positioned in a protein loop and is suitable for protein contact [38]. Thus, it is possible to speculate that Vif interaction with APOBEC3G at this position might alter protein conformation changing its biochemical and biophysical properties in ways that are larger than that normally expected from altering just one amino acid position in a protein. Elegant studies on the involvement of D128 in species specificity of Vif to counteract APOBEC3G function are, in part, consistent with this hypothesis [37-40]. Additionally, the D to K amino acid change at position 128 of APOBEC3G may alter the negative electrostatic interaction of aspartate to a positively charged amino acid which may inhibit Vif-induced allosteric changes. Conversely, if APOBEC3G from African green monkey, AGM, cells is considered, the positively charged lysine 128 found in this protein cannot interact with HIV-1 Vif but may instead do so with SIVAGM Vif, probably by using a negatively charged protein pocket. Thus, one idea is that conformational changes can result only from species-specific interaction between Vif and its cognate APOBEC3G. Although this model may be attractive, further refinements should be investigated since the isoelectric points of HIV-1 Vif and SIVAGM Vif are similar. Indeed, this assumption could be tested by studies similar to those of Kao et al using APOBEC3G with SIVAGM Vif or HIV-2 Vif, together with the role of these proteins in the context of APOBEC3F [41,42].
###end p 10
###begin p 11
###xml 15 24 15 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kao et al</italic>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 522 524 522 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 984 988 984 988 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF </sup>
###xml 1246 1255 1246 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kao et al</italic>
###xml 1423 1424 1423 1424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 967 972 <span type="species:ncbi:9606">human</span>
In the work of Kao et al., the authors explored the possibility that the different expression systems used by them and others could explain the discrepant results obtained on Vif-induced APOBEC3G depletion. For this hypothesis to hold several factors may be envisioned to interfere with the APOBEC3G-depletion mechanism of Vif. For example, one way to stabilize and activate p53 in cells is by interfering either with the interaction of MDM2 and p53 or with the ability of MDM2 to target its bound p53 for degradation [34,35]. Making a parallel between MDM2-p53 and Vif-APOBEC3G, two mechanisms can be hypothesized: one through changes in both proteins due to covalent modifications, and the other through non-covalent regulation of Vif-APOBEC3G association. In the case of MDM2-p53, it is apparent that both mechanisms are observed under different experimental conditions: induced phosphorylation of p53 can attenuate the p53-MDM2 interaction, and alternatively the human protein p14ARF can bind to MDM2 and prevent its destruction of p53. Interestingly, these two mechanisms of p53 regulation appear to be entirely independent of each other, and emanated through distinct signal pathways. Using this parallel, one cautions that the findings of Kao et al. of a lack of APOBEC3G depletion do not rule out the possibility that Vif, under different conditions, can mediate proteasome dependent degradation of this deaminase [1].
###end p 11
###begin p 12
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1074 1076 1074 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1253 1255 1253 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1256 1258 1256 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
Further research directions can be designed to evaluate additional putative regulatory mechanisms of APOBEC3G activity. For example, exposure of cells to a variety of extracellular stimuli leads to the rapid phosphorylation, ubiquitination, and ultimately proteolytic degradation of cellular proteins like IkappaB, which frees NF-kappaB to translocate to the nucleus where it regulates gene transcription [36]. NF-kappaB activation represents a paradigm for controlling the function of a regulatory protein via ubiquitination-dependent proteolysis, as an integral part of a phosphorylation based signaling cascade. After phosphorylation, the IKK phosphoacceptor sites on IkappaB serve as an essential part of a specific recognition site for E3RS (IkappaB/beta-TrCP), a SCF-type E3 ubiquitin ligase, thereby explaining how IKK controls IkappaB ubiquitination and degradation. A parallel may be envisaged for the regulation of Vif-induced APOBEC3G ubiquitination and the consequent depletion. It was reported recently that Vif is monoubiquitinated in the absence of APOBEC3G [28]. In addition, when Vif is co-expressed with APOBEC3G it is polyubiquitinated and rapidly degraded, suggesting that co-expression accelerates the degradation of both proteins [28,43]. Furthermore, mutations of conserved phosphorylation sites in Vif impair viral replication but do not affect APOBEC3G degradation, suggesting that Vif is important for other functions in addition to inducing proteasomal degradation of APOBEC3G. Whether or not phosphorylation regulates polyubiquitination or monoubiquitination is another open question.
###end p 12
###begin p 13
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kao et al</italic>
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 555 558 555 558 <sub xmlns:xlink="http://www.w3.org/1999/xlink">off</sub>
###xml 777 786 777 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kao et al</italic>
###xml 1216 1218 1216 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1219 1221 1219 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1697 1702 1697 1702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 1958 1959 1958 1959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1987 1996 1987 1996 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kao et al</italic>
###xml 1788 1793 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2144 2149 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2226 2231 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Kao et al. interestingly also reported that expression of Vif from a codon-optimized vector had a more pronounced effect on APOBEC3G steady-state levels than wild-type Vif from pNL-A1 [1,44]. Even though the expression level of Vif-optimized construct is lower than wild-type, it is conceivable that its intracellular half-life may be increased affecting the quality and constancy of Vif-APOBEC3G association. Supporting this hypothesis are results where the authors showed a partial co-localization of Vif and APOBEC3G which may be indicative of higher koff, typically resulting from a lower protein affinity. This type of finding will not be observable by physical interaction assays which employ Western blotting since only stronger bindings are detected by such technique. Kao et al. remarkably demonstrated that infectious viruses are obtained in the presence of various ratios of APOBEC3G and Vif. Nevertheless, the question of whether under their conditions APOBEC3G and/or Vif are incorporated into viral particles remains pertinent. If the deaminase is not incorporated into the viral particle, then Vif may directly or indirectly inhibit the interaction of APOBEC3G with Gag polyproteins in the cytoplasm [45,46]. If APOBEC3G is included in the virion, then a direct blocking of its cytidine deaminase activity by Vif can be hypothesized. To date, a direct blocking of cytidine deaminase activity in the cytoplasm that consequently inhibits APOBEC3G interaction cannot be excluded. In fact, our own studies with a bacterial deaminase system where Vif and APOBEC3G are co-expressed show that Vif-mediated interaction with APOBEC3G can inhibit its cytidine deaminase activity (Santa-Marta et al; manuscript submitted). These results strongly support a new mechanistic function of HIV-1 Vif protein, complementing the model where Vif counteracts the inhibitory effects of APOBEC3G by enhancing its degradation via ubiquitin-proteasome pathway (Figure 1). The findings reported by Kao et al. together with the direct effects of Vif on the activity of cytidine deaminase (our work) may indicate an alternative protective mechanism used by HIV-1 to eliminate innate cellular immunity. Nevertheless, we cannot exclude that HIV-1 uses Vif to exert multiple mechanisms to synergistically and more effectively inhibit the anti-viral activity of APOBEC3G.
###end p 13
###begin p 14
In conclusion, the existence of two different mechanisms may represent two faces of the same coin, with the common goal of inhibiting APOBEC3G's anti-viral activity. As is often the case with new findings, new questions are posed. The link between APOBEC3G's enzymatic function, its degradation pathway, and its incorporation into virions in the presence of Vif is certainly to require additional attention. Answers to these questions are likely to keep many of us busy for the foreseeable future.
###end p 14
###begin title 15
Competing Interests
###end title 15
###begin p 16
None declared.
###end p 16
###begin title 17
Abbreviations
###end title 17
###begin p 18
###xml 28 33 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 35 63 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 104 107 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
###xml 109 138 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
The abbreviations used are: HIV-1, human immunodeficiency virus, type 1; Vif, Viral Infectivity Factor; SIV, simian immunodeficiency virus; NC, nucleocapsid protein; APOBEC3G, apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G; APOBEC3F, apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3F PBMC, peripheral blood mononuclear cells; Cul5, Cullin type 5; SCF, skp1-cullin-F-box protein ligase.
###end p 18
###begin title 19
Acknowledgments
###end title 19
###begin p 20
JG and MSM are supported by PSIDA/MGI/49729/2003 (Fundacao para a Ciencia e Tecnologia).
###end p 20
###begin article-title 21
###xml 25 60 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells
###end article-title 21
###begin article-title 22
Death and the retrovirus
###end article-title 22
###begin article-title 23
###xml 14 31 <span type="species:ncbi:10407">hepatitis B virus</span>
Inhibition of hepatitis B virus replication by APOBEC3G
###end article-title 23
###begin article-title 24
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein
###end article-title 24
###begin article-title 25
DNA deamination mediates innate immunity to retroviral infection
###end article-title 25
###begin article-title 26
###xml 17 22 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Hypermutation of HIV-1 DNA in the absence of the Vif protein
###end article-title 26
###begin article-title 27
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA
###end article-title 27
###begin article-title 28
###xml 32 37 <span type="species:ncbi:9606">human</span>
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts
###end article-title 28
###begin article-title 29
###xml 15 50 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Role of Vif in human immunodeficiency virus type 1 reverse transcription
###end article-title 29
###begin article-title 30
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif
###end article-title 30
###begin article-title 31
###xml 10 16 <span type="species:ncbi:9986">rabbit</span>
###xml 86 91 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity
###end article-title 31
###begin article-title 32
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sor </italic>
###xml 16 21 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The sor gene of HIV-1 is required for efficient virus transmission in vitro
###end article-title 32
###begin article-title 33
###xml 4 7 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The HIV 'A' (sor) gene product is essential for virus infectivity
###end article-title 33
###begin article-title 34
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vif </italic>
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vpr </italic>
###xml 32 67 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products
###end article-title 34
###begin article-title 35
###xml 19 54 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells
###end article-title 35
###begin article-title 36
###xml 30 65 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes
###end article-title 36
###begin article-title 37
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection
###end article-title 37
###begin article-title 38
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Vif mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity
###end article-title 38
###begin article-title 39
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cell-free transmission of Vif mutants of HIV-1
###end article-title 39
###begin article-title 40
###xml 36 71 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Cellular and viral specificities of human immunodeficiency virus type 1 vif protein
###end article-title 40
###begin article-title 41
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Evidence for a newly discovered cellular anti-HIV-1 phenotype
###end article-title 41
###begin article-title 42
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein
###end article-title 42
###begin article-title 43
###xml 32 67 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Role of Vif in stability of the human immunodeficiency virus type 1 core
###end article-title 43
###begin article-title 44
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability
###end article-title 44
###begin article-title 45
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif
###end article-title 45
###begin article-title 46
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation
###end article-title 46
###begin article-title 47
###xml 4 39 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity
###end article-title 47
###begin article-title 48
###xml 19 22 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 51 56 <span type="species:ncbi:9606">human</span>
The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G
###end article-title 48
###begin article-title 49
Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway
###end article-title 49
###begin article-title 50
###xml 65 100 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G
###end article-title 50
###begin article-title 51
###xml 59 64 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex
###end article-title 51
###begin article-title 52
ER quality control: the cytoplasmic connection
###end article-title 52
###begin article-title 53
Mechanisms underlying ubiquitination
###end article-title 53
###begin article-title 54
A role for ubiquitin ligase recruitment in retrovirus release
###end article-title 54
###begin article-title 55
Signaling to p53: breaking the MDM2-p53 circuit
###end article-title 55
###begin article-title 56
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
###end article-title 56
###begin article-title 57
Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity
###end article-title 57
###begin article-title 58
A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action
###end article-title 58
###begin article-title 59
A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif)
###end article-title 59
###begin article-title 60
###xml 104 107 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor
###end article-title 60
###begin article-title 61
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion
###end article-title 61
###begin article-title 62
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 50 85 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication
###end article-title 62
###begin article-title 63
###xml 9 14 <span type="species:ncbi:9606">human</span>
###xml 69 74 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 79 84 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins
###end article-title 63
###begin article-title 64
###xml 19 54 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The Vif protein of human immunodeficiency virus type 1 is posttranslationally modified by ubiquitin
###end article-title 64
###begin article-title 65
###xml 26 31 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression
###end article-title 65
###begin article-title 66
Functional domains of APOBEC3G required for antiviral activity
###end article-title 66
###begin article-title 67
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The interaction between HIV-1 Gag and APOBEC3G
###end article-title 67
###begin article-title 68
APOBEC-mediated editing of viral RNA
###end article-title 68
###begin article-title 69
###xml 21 26 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Recent insights into HIV-1 Vif
###end article-title 69

